Drug intelligence / Profile preview

angiotensin-(3-4)

Development stage
Preclinical
Modality
Peptides
Administration
Oral
01

Overview

Angiotensin-(3-4) (Ang-(3-4) or Val-Tyr) is the shortest peptide derived from angiotensin II, consisting of the dipeptide valine and tyrosine. It is formed through successive hydrolysis of longer angiotensins in both plasma and kidney, making it a component of the systemic and organ-based renin–angiotensin system. Angiotensin-(3-4) acts as a potent antihypertensive agent in humans and rats, primarily by inhibiting fluid reabsorption in renal proximal tubule cells, leading to increased urinary sodium excretion. Mechanistically, it counteracts effects mediated by the angiotensin II type 1 receptor (AT1R) by acting as an allosteric enhancer at the angiotensin II type 2 receptor (AT2R). This action modulates ATP-dependent Ca²⁺ and Na⁺ transporters via a cAMP-dependent protein kinase pathway. It is orally bioavailable due to its resistance to hydrolysis and high intestinal permeability[1][3].

Other names
Ang-(3-4)Val-Tyr
02

Targets

AGTR2 (AT2)

Beyond the preview

Go deeper on angiotensin-(3-4).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on angiotensin-(3-4).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call